Real-World Survival Outcomes of Hypomethylating Agents and Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndromes: A Retrospective Single-Center Experience
Hemato · 13.08.2026 · 7 (3) · 27
DOI: 10.3390/hemato7030027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hemato, online erschienen am 13.08.2026. Verfasst von Kamil Deveci und 2 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Treatment strategies for myelodysplastic syndromes (MDS) range from supportive care to disease-modifying therapies, depending on risk stratification and patient characteristics. Hypomethylating agents (HMAs) remain the standard treatment for higher-risk disease, whereas allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only potentially curative option. This study evaluated real-world survival outcomes and prognostic factors in patients with MDS treated with HMAs or allo-HSCT.
Methods
A total of 79 patients with MDS who received azacitidine, decitabine, or allo-HSCT were retrospectively analyzed. Overall survival (OS) was evaluated using Kaplan–Meier and Cox proportional hazards analyses. To address potential immortal time bias, a prespecified 6-month landmark analysis was additionally performed.
Results
Median OS was 14.9 months (95% CI, 9.9–20.0) with azacitidine, 10.0 months (95% CI, 6.8–13.2) with decitabine, and 48.0 months (95% CI, 19.9–76.1) after allo-HSCT. Patients undergoing allo-HSCT were significantly younger and had better ECOG performance status than those receiving HMAs. After adjustment for age, ECOG performance status, and IPSS-R risk category, treatment modality remained significantly associated with OS in the multivariable Cox regression model. In the prespecified 6-month landmark analysis, the survival advantage associated with allo-HSCT remained significant, although the adjusted association was attenuated.
Conclusions
In this real-world cohort of actively treated patients with MDS, allo-HSCT was associated with longer overall survival than HMAs. Although this association persisted after adjustment for major clinical confounders and in a landmark analysis addressing immortal time bias, residual confounding related to treatment selection cannot be excluded. These findings should therefore be interpreted as an association rather than evidence of a causal treatment effect.
Zitieren
APA
Deveci, K., Yildizhan, E., & Unal, A. (2026). Real-World Survival Outcomes of Hypomethylating Agents and Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndromes: A Retrospective Single-Center Experience. Hemato, 7(3), 27. https://doi.org/10.3390/hemato7030027
Vancouver
Deveci K, Yildizhan E, Unal A. Real-World Survival Outcomes of Hypomethylating Agents and Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndromes: A Retrospective Single-Center Experience. Hemato. 2026;7(3):27. doi:10.3390/hemato7030027
BibTeX
@article{Deveci2026,
author = {Deveci, Kamil and Yildizhan, Esra and Unal, Ali},
title = {Real-World Survival Outcomes of Hypomethylating Agents and Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndromes: A Retrospective Single-Center Experience},
journal = {Hemato},
year = {2026},
volume = {7},
number = {3},
pages = {27},
doi = {10.3390/hemato7030027}
}
EUVIMED